JMJD2A (KDM4A) (1-350), His-Tag Recombinant

Catalog #

50123

$465 *

Size: 100 µg

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant human JMJD2A, also known KDM4A (lysine-specific demethylase 4A), encompassing amino acids 1-350. This construct contains an N-terminal His-tag (6xHis). This protein was affinity purified.

This product has been cited 3 times.

●

Synonyms

KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677, Lysine-specific demethylase 4A, JmjC domain-containing histone demethylation protein 3A, Jumonji domain-containing protein 2A, [histone H3]-trimethyl-L-lysine(36) demethylase 4A

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

JMJD2A Activity

JMJD2A (KDM4A) inhibition curve using an AlphaLISA assay (#50413). Representative data only; data may vary by lot.

Product Info

Storage and Usage

Citations3

Species

Human

Construct

JMJD2A (His-1-350)

Host Species/Expression System

E. coli

Purity

≥90%

Format

Aqueous buffer solution

Formulation

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, variable imidazole, and 20% glycerol

42 kDa

Amino Acids

1–350

Specific Activity

0.084 pmole/min/μg

Genbank #

NM_014663

UniProt #

O75164

Tag(s)

N-terminal His-tag

Background

JMJD2A, also known as KDM4A (lysine-specific demethylase 4A), belongs to the Jumonji domain 2 family of proteins and the alpha-ketoglutarate-dependent hydroxylase superfamily and is involved in epigenetic regulation of transcription factors. Its action impacts cell proliferation and development. It converts trimethylated histones on histone H3 lysines 9 and 36 specifically (H3K9me2/3 and H3K9me2/me3) into demethylated forms. It is involved in myogenic differentiation by inhibiting Gas-9-dependent MyoD (myoblast determination protein 1) degradation, being a key regulator of skeletal muscle development and regeneration. It has been linked to cancer, and overexpression of JMJD2A is found in colon and lung cancer. It seems to promote cancer progression by regulating other oncogenes. Inhibition of JMJD2A in cancer lines was able to lead to cell cycle arrest and cancer metastasis. A deeper understanding of its functions and development of targeted therapies may prove beneficial for patients with JMJD2A-related diseases.

References

Zhang, D., et al. (2005). Mol. Cell Biol. 25(15): 6404-6414.
Gray SG, et al. (2005). J. Biol. Chem. 280 (31): 28507–18.

Storage/Stability

At least 6 months at -80°C.

Assay Conditions

A 10 µl reaction mix containing assay buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 500 µM α-ketoglutarate, 25 µM iron, 2 mM ascorbic acid, 0.01% Tween-20), 0.5 µM biotinylated peptide substrate, and JMJD2A (100-400 ng) was added to the wells. An antibody against demethylated K9 peptide was added and the reactions were incubated for 30 minutes. Streptavidin-conjugated secondary antibody was added, followed by Alpha Screening detection.

Instructions for Use

Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.

Applications

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

Shipping Temperature

-80°C

Warnings

Avoid freeze/thaw cycles.

Scientific Category

Demethylase

Regulatory Status

Research Use Only